Clinical trial · Interventional
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
NCT04508725CI-TRIAL-00092636completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doppler Ultrasound | Diagnostic Test | — | UNRESOLVED |
| SIEMENS S3000 and Verasonics Vantage 256 | Device | — | UNRESOLVED |
| Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI | Drug | — | UNRESOLVED |
| Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- description
- Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- interventionNames
- Diagnostic Test: Doppler Ultrasound
- Device: SIEMENS S3000 and Verasonics Vantage 256
- Drug: Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- type
- ACTIVE_COMPARATOR
- label
- Non-ICI therapy
- description
- Patients are planned to be treated with non-ICI therapy
- interventionNames
- Diagnostic Test: Doppler Ultrasound
- Device: SIEMENS S3000 and Verasonics Vantage 256
- Drug: Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Pathology-confirmed diagnosis of Renal cell carcinoma (RCC) * At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging * Written informed consent. Specific inclusion criteria: * Arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) * Arm 2: planned to be treated with non-ICI therapy Exclusion Criteria: -Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.